EHA 2019 | What’s to come for MDS therapy?

David Sallman

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the treatment options for high-risk myelodysplastic syndromes (MDS). Dr Sallman specifically mentions the use of azacitidine in combination with APR-246. Speaking at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Dr Sallman also mentions venetoclax and molecular-based therapies such as IDH1 and IDH2 inhibitors.

Share this video